Patent ID: 8580773

Claim:
A method of inhibiting the androgen receptor, the method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound of Formula I: wherein each R 1 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, —SR 4 , —NR 4 R 5 , cycloalkyl, heterocycloalkyl, aryl and heteroaryl; R 2 is selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 alkyl-OH, C 2-6 alkenyl and C 2-6 alkynyl; R 3 is aryl, optionally substituted with from 1 to 3 R 6 groups; R 4 and R 5 are each independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 2-6 alkenyl and C 2-6 alkynyl; or R 4 and R 5 are combined with the nitrogen to which they are attached to form a heterocyclic ring having from 5 to 7 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S; each R 6 is independently selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl and C 1-6 alkoxy; L is a linker selected from the group consisting of C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene and C 3-6 cycloalkylene; X is a heteroaryl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with from 1 to 3 R 8 groups; each R 8 is independently selected from the group consisting of H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl and C 1-6 alkoxy; and salts, hydrates and prodrugs thereof, thereby inhibiting the androgen receptor.